(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
(8)检查点抑制剂患者发生自身免疫内分泌疾病的机制
基本信息
- 批准号:10406245
- 负责人:
- 金额:$ 55.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Addison&aposs diseaseAddressAdverse eventAffectAftercareAntigensAutoantigensAutoimmuneAutoimmune DiabetesAutoimmune ProcessAutoimmune ResponsesB cell repertoireB-LymphocytesBeta CellBiological MarkersBlocking AntibodiesBloodCD8-Positive T-LymphocytesCTLA4 geneCellsClinicalDataDefectDevelopmentDiabetes MellitusDiseaseDoseEndocrineEndocrine System DiseasesEventFailureFrequenciesFunctional disorderHLA-A2 AntigenHashimoto DiseaseImmuneImmune checkpoint inhibitorImmune responseImmunologicsImmunologistInbred NOD MiceIndividualInfusion proceduresInsulin-Dependent Diabetes MellitusIntensive CareInterleukin-2InterventionKnowledgeLeadLibrariesLifeLife ExpectancyLigandsMalignant NeoplasmsMalignant neoplasm of lungModelingModificationMolecularMonoclonal AntibodiesMorbidity - disease rateOncologistPD-1 inhibitorsPancreasPathologicPatientsPeripheralPharmaceutical PreparationsPhenotypePre-Clinical ModelPrimary NeoplasmRegimenRegulatory T-LymphocyteRenal Cell CarcinomaReportingRiskSamplingSerious Adverse EventSubgroupT cell responseT-Cell ActivationT-Cell ReceptorT-LymphocyteTechniquesTestingThyroid DiseasesThyroid GlandThyroiditisTimeTissuesanti-PD-1anti-PD-L1anti-PD-L1 antibodiesanti-PD1 antibodiesantitumor effectautoimmune endocrine disorderautoreactive B cellautoreactive T cellautoreactivitybiomarker developmentcancer therapycheckpoint therapychemotherapycytokinediabetogenicdrug biological activityeffector T cellimmune-related adverse eventsimprovedipilimumabmelanomamouse modelpreventprogrammed cell death protein 1prospectiveresponsesample collectiontooltranscriptometranscriptome sequencingtreatment strategytumor
项目摘要
Summary
Checkpoint inhibitor (CPI) therapy has greatly improved the treatment of cancers that had previously been
considered intractable. As a result of the intended biologic activity of these drugs, which enable activation of T
cells that can cause tumor destruction, new autoimmune adverse events have occurred. Major targets of these
adverse events have been endocrine tissues including thyroid and beta cells in the pancreas. Thyroiditis is
frequent and autoimmune diabetes has emerged as a serious adverse event often requiring intensive care.
The reasons why some individuals develop these autoimmune events and why some are protected are not
known but this information may lead to ways of preventing the occurrence of these adverse events. The overall
objective if this proposal is to understand the molecular and cellular immunologic basis for autoimmune
diabetes and thyroid disease and to test whether they can be prevented with agents that are specific in their
actions. The hypothesis that we wish to test is that in individuals who develop endocrinopathies CPI therapy
induces pathologic T cells, loss of B cell tolerance, and dysfunctional regulatory T cells. Our preliminary data
has identified phenotypic differences in autoantigen reactive effector T cells and Tregs in those who do and do
not develop endocrinopathies. In addition, our analysis of autoreactive B cells suggests that CPI therapy
affects peripheral B cell tolerance checkpoints and results in an increased frequency of autoreactive mature
naïve B cells. We plan to analyze, using Seq-Well single cells in patients who are followed prospectively from
before treatment to when they present with autoimmune endocrinopathies. In the subgroup of individuals who
are HLA-A2 (~40%) we will study thyroid and diabetes reactive CD8+ T cells with cellular libraries and CyTOF
and determine whether the T cell receptors that are found on the antigen reactive cells can be detected prior to
treatment and in which subpopulation. We will also determine whether CPIs affect the number and function of
Tregs and address specifically whether the CPI causes the Tregs to produce pathologic cytokines. We will use
established techniques to determine whether the CPIs induce a failure of peripheral B cell tolerance and
identify the relationship between changes in B cells and Tregs. We will be collecting data on the autoreactive T
and B cell repertoire that we will correlate with clinical responses to the primary tumors. Finally, our studies of
the immunologic mechanisms that underlie these adverse events suggest ways in which they may be
prevented, which we will test in a murine model of anti-PD-L1 induced diabetes in NOD mice. We will test
whether B cell depletion or enhancement of Tregs, either by low doses of IL-2 or by infusion of diabetes
antigen specific Tregs can prevent diabetes onset. These studies therefore, will elucidate the mechanisms of
these serious adverse events, identify individuals who are at greatest risk for these events, and test whether
therapies that do not interfere with the anti-tumor effects of the CPIs can be used to prevent them.
总结
检查点抑制剂(CPI)疗法极大地改善了以前被认为是治疗癌症的方法。
被认为是棘手的。由于这些药物的预期生物活性,其能够激活T细胞,
细胞,可导致肿瘤破坏,新的自身免疫不良事件发生。这些主要目标
不良事件是内分泌组织,包括甲状腺和胰腺中的β细胞。甲状腺炎是
频繁的自身免疫性糖尿病已经成为一种严重的不良事件,经常需要加强护理。
一些个体发生这些自身免疫事件以及一些个体受到保护的原因并不清楚。
已知,但这些信息可能会导致预防这些不良事件发生的方法。整体
目的了解自身免疫性疾病的分子和细胞免疫学基础,
糖尿病和甲状腺疾病,并测试它们是否可以用特异性的药物来预防。
行动我们希望检验的假设是,在发生内分泌疾病的个体中,CPI治疗
诱导病理性T细胞、B细胞耐受性丧失和功能失调的调节性T细胞。我们的初步数据
已经确定了在那些做和不做的人中自身抗原反应性效应T细胞和T细胞的表型差异
而不是内分泌失调此外,我们对自身反应性B细胞的分析表明,CPI治疗
影响外周B细胞耐受性检查点,并导致自身反应性成熟
幼稚B细胞。我们计划使用Seq-Well单细胞对前瞻性随访的患者进行分析
从治疗前到出现自身免疫性内分泌病在那些
是HLA-A2(~40%),我们将使用细胞文库和CyTOF研究甲状腺和糖尿病反应性CD 8 + T细胞
并确定在抗原反应性细胞上发现的T细胞受体是否可以在
治疗和亚群。我们亦会研究消费物价指数是否影响
并具体说明CPI是否导致TCRs产生病理性细胞因子。我们将使用
确定CPI是否诱导外周B细胞耐受失败的已建立的技术,
确定B细胞变化与T细胞的关系。我们将收集自体反应T细胞的数据
和B细胞库,我们将与原发性肿瘤的临床反应相关联。最后,我们的研究
这些不良事件背后的免疫学机制表明,
预防,我们将在NOD小鼠中的抗PD-L1诱导的糖尿病的鼠模型中测试。我们将测试
无论是B细胞耗竭还是通过低剂量IL-2或通过输注糖尿病
抗原特异性TGFAP可预防糖尿病发作。因此,这些研究将阐明
这些严重不良事件,确定这些事件的最大风险个体,并测试是否
可以使用不干扰CPI的抗肿瘤作用的疗法来预防它们。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report.
- DOI:
- 发表时间:2021-01
- 期刊:
- 影响因子:0
- 作者:Jessel S;Austin M;Kluger HM
- 通讯作者:Kluger HM
Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy.
- DOI:pii: 157
- 发表时间:2021-01
- 期刊:
- 影响因子:0
- 作者:Unlu S;Grant MJ;Gettinger S;Adeniran A;Kluger HM
- 通讯作者:Kluger HM
Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity.
- DOI:10.1371/journal.pone.0246764
- 发表时间:2021
- 期刊:
- 影响因子:3.7
- 作者:Higgins AY;Arbune A;Soufer A;Ragheb E;Kwan JM;Lamy J;Henry M;Cuomo JR;Charifa A;Gallegos C;Hull S;Coviello JS;Bader AS;Peters DC;Huber S;Mojibian HR;Sinusas AJ;Kluger H;Baldassarre LA
- 通讯作者:Baldassarre LA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kevan C Herold其他文献
Prevention of type 1 diabetes: the time has come
预防 1 型糖尿病:时机已到
- DOI:
10.1038/ncpendmet0832 - 发表时间:
2008-04-29 - 期刊:
- 影响因子:40.000
- 作者:
Jennifer Sherr;Jay Sosenko;Jay S Skyler;Kevan C Herold - 通讯作者:
Kevan C Herold
Drug Insight: new immunomodulatory therapies in type 1 diabetes
药物洞察:1 型糖尿病的新型免疫调节疗法
- DOI:
10.1038/ncpendmet0082 - 发表时间:
2006-02-01 - 期刊:
- 影响因子:40.000
- 作者:
Simona Cernea;Kevan C Herold - 通讯作者:
Kevan C Herold
Kevan C Herold的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kevan C Herold', 18)}}的其他基金
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes
自身免疫性糖尿病中β细胞和免疫细胞的适应性表观遗传机制
- 批准号:
10279176 - 财政年份:2021
- 资助金额:
$ 55.48万 - 项目类别:
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes
自身免疫性糖尿病中β细胞和免疫细胞的适应性表观遗传机制
- 批准号:
10656313 - 财政年份:2021
- 资助金额:
$ 55.48万 - 项目类别:
Effects of EBV on autoimmunity and responses to immune therapy
EBV 对自身免疫和免疫治疗反应的影响
- 批准号:
10353823 - 财政年份:2021
- 资助金额:
$ 55.48万 - 项目类别:
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes
自身免疫性糖尿病中β细胞和免疫细胞的适应性表观遗传机制
- 批准号:
10451626 - 财政年份:2021
- 资助金额:
$ 55.48万 - 项目类别:
Effects of EBV on autoimmunity and responses to immune therapy
EBV 对自身免疫和免疫治疗反应的影响
- 批准号:
10493414 - 财政年份:2021
- 资助金额:
$ 55.48万 - 项目类别:
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
(8)检查点抑制剂患者发生自身免疫内分泌疾病的机制
- 批准号:
10152527 - 财政年份:2018
- 资助金额:
$ 55.48万 - 项目类别:
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
(8)检查点抑制剂患者发生自身免疫内分泌疾病的机制
- 批准号:
9927053 - 财政年份:2018
- 资助金额:
$ 55.48万 - 项目类别:
Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy
检查点抑制剂免疫治疗的自身免疫新诊断
- 批准号:
9466612 - 财政年份:2017
- 资助金额:
$ 55.48万 - 项目类别:
Phase II trial of extended release exenatide (Bydureon) and teplizumab in patients with new onset Type 1 Diabetes.
在新发 1 型糖尿病患者中进行缓释艾塞那肽 (Bydureon) 和 teplizumab 的 II 期试验。
- 批准号:
9143838 - 财政年份:2016
- 资助金额:
$ 55.48万 - 项目类别:
Epigenetic, Protein, and Cellular Biomarkers of Beta Cell Function in T1D
T1D β 细胞功能的表观遗传、蛋白质和细胞生物标志物
- 批准号:
8813784 - 财政年份:2014
- 资助金额:
$ 55.48万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 55.48万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 55.48万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 55.48万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 55.48万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 55.48万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 55.48万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 55.48万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 55.48万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 55.48万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 55.48万 - 项目类别: